Amr Radwan
Research Subjects
Amr Radwan has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Changming Xia
Regeneron Pharmaceuticals Inc., Tarrytown, NY
2 shared publications - Alain Schoepfer
Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois University of Lausanne Lausanne Switzerland
1 shared publication - Angela Khodzhayev
Regeneron Pharmaceuticals, Inc. , 777 Old Saw Mill River Rd, Tarrytown, NY 10591
1 shared publication - David Woojin Jang
Department of Head and Neck Surgery & Communication Sciences Duke University School of Medicine Durham North Carolina USA
1 shared publication - Eckard Hamelmann
Children’s Center Bethel, Protestant Hospital Bethel, University Hospital OWL, University of Bielefeld, Bielefeld, Germany
1 shared publication - Eilish McCann
Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (10) , 2322-2333.e12
Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level
- 19 June 2026
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 14 (10) , 2322-2333.e12
Open AccessDupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level
- Open Access
- 3 March 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (2)
Burden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis
Summary: Background: Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality of life (QoL) of EoE patients. Methods: The multicountry cross-sectional survey, Adelphi EoE Disease Specific Programme™, collected physician and patient-reported data on clinical characteristics, HCRU, symptoms, comorbidities, and QOL of EoE patients with past/current proton pump inhibitor use and ongoing dysphagia-related symptoms (September to December 2020) at study entry. Results: Physicians provided clinical characteristics, symptom, comorbidity, and HCRU data for 412 patients (12–17 years: 8%; ≥18 years: 92%); and 161 of these patients (12–17 years: 6%; ≥18 years: 94%) provided symptom and QOL data. Of the 412 patients, 67% were male, with a mean (SD) age of 37.0 (15.3) years. Overall, 74% of patients were currently being treated with corticosteroids (12–17 years: 88%; ≥18 years: 73%); 25% of patients had a history of esophageal dilations (12–17 years: 19%; ≥18 years: 26%); and 30% of patients had EoE-related emergency room visit (12–17 years: 31%; ≥18 years: 30%) in the last year. Among the 161 patients, heartburn (69%) was the most commonly reported symptom; the greatest negative impacts on QOL were reported for dysphagia-related anxiety, social activities involving food, and maintaining friendships (EoE Impact Questionnaire scores [1–5, low to high impact]: 1.6–2.2 for both age groups). Conclusion: EoE patients continued to experience disease burden despite receiving treatment, highlighting the high unmet need for effective disease management in this population.
- 3 March 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (2)
Open AccessBurden of eosinophilic esophagitis in adult and adolescent patients: results from a real-world analysis
Summary: Background: Real-world data on the impact of eosinophilic esophagitis (EoE) in patients are limited. This study assessed clinical characteristics, healthcare resource utilization (HCRU), symptoms, comorbidities, and quality of life (QoL) of EoE patients. Methods: The multicountry cross-sectional survey, Adelphi EoE Disease Specific Programme™, collected physician and patient-reported data on clinical characteristics, HCRU, symptoms, comorbidities, and QOL of EoE patients with past/current proton pump inhibitor use and ongoing dysphagia-related symptoms (September to December 2020) at study entry. Results: Physicians provided clinical characteristics, symptom, comorbidity, and HCRU data for 412 patients (12–17 years: 8%; ≥18 years: 92%); and 161 of these patients (12–17 years: 6%; ≥18 years: 94%) provided symptom and QOL data. Of the 412 patients, 67% were male, with a mean (SD) age of 37.0 (15.3) years. Overall, 74% of patients were currently being treated with corticosteroids (12–17 years: 88%; ≥18 years: 73%); 25% of patients had a history of esophageal dilations (12–17 years: 19%; ≥18 years: 26%); and 30% of patients had EoE-related emergency room visit (12–17 years: 31%; ≥18 years: 30%) in the last year. Among the 161 patients, heartburn (69%) was the most commonly reported symptom; the greatest negative impacts on QOL were reported for dysphagia-related anxiety, social activities involving food, and maintaining friendships (EoE Impact Questionnaire scores [1–5, low to high impact]: 1.6–2.2 for both age groups). Conclusion: EoE patients continued to experience disease burden despite receiving treatment, highlighting the high unmet need for effective disease management in this population.
- Open Access
- 2 January 2025
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 46 (2) , 104596
Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registry
- 2 January 2025
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 46 (2) , 104596
Open AccessBaseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registry